TheraRadar
← Back
Data updated: May 24, 2026

INFORLIFE

Generics

INFORLIFE is a generic drug manufacturer focused on Cardiovascular, Infectious Disease. Key products include MIDAZOLAM IN 0.9% SODIUM CHLORIDE.

2008
Since
11
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 67%
2 drugs
Infectious Disease 33%
1 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE leads revenue
  • 4 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling